RxDoctor Payments Data

Tommie Cassidy, NP

Family · Springhill, LANPI 1982861621

Payments from drug & device makers

$803in general payments, 2019–2025

Across 59 payments — averaging $13.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Getinge USA Sales, LLC$201
  • AbbVie$142
  • Novo Nordisk$70
  • Lilly USA, LLC$60
  • Boehringer Ingelheim$59
  • GSK$55
  • plus $216 from 7 others

What the payments were for

  • Food & beverage$803100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$803 in reported general payments places this provider in the 55th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$2,673
Medicare patients
25
Services billed
77

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin73$66,693
OzempicSemaglutide46$51,514
TrulicityDulaglutide40$44,860
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$28,837
EliquisApixaban25$18,520
JanuviaSitagliptin Phosphate22$12,252
JanumetSitagliptin Phos/Metformin Hcl19$10,195
LinzessLinaclotide12$10,082
MyrbetriqMirabegron17$9,530
FarxigaDapagliflozin Propanediol13$7,314
Janumet XrSitagliptin Phos/Metformin Hcl11$5,946
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$4,463
Dexlansoprazole DrDexlansoprazole21$3,950
Gabapentin155$2,049
Albuterol Sulfate HfaAlbuterol Sulfate77$1,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$59$66,69373 claims
Novo NordiskOzempic$70$51,51446 claims
Lilly USA, LLCTrulicity$60$44,86040 claims
GSKTrelegy Ellipta$55$28,83729 claims
PfizerEliquis$42$18,52025 claims
AbbVieLinzess, Synthroid$142$11,04634 claims
Astellas Pharma US IncMyrbetriq$14$9,53017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,610 family providers in Louisiana.

Other family in Springhill

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →